

**Report of the**  
**Fifth Consultative Meeting**  
**on**  
***Leishmania*/HIV Coinfection**

Addis Ababa, Ethiopia, 20–22 March 2007



**World Health  
Organization**



Report of the  
Fifth Consultative Meeting  
on  
*Leishmania*/HIV Coinfection

Addis Ababa, Ethiopia, 20–22 March 2007



The World Health Organization gratefully acknowledges the financial support provided to this meeting by the "Agencia Española de Cooperación Internacional para el Desarrollo"

© World Health Organization 2007

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [permissions@who.int](mailto:permissions@who.int)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed by the WHO Document Production Services, Geneva, Switzerland

# Contents

## **1. Introduction**

1.1 HIV/AIDS: statistics and features	1
1.2 Leishmaniasis: statistics and features	2
1.3 <i>Leishmania</i> /HIV coinfection: statistics and features	2

## **2. Epidemiological information on *Leishmania*/HIV coinfection**

2.1 Southern Europe	3
2.2 South-east Asia	5
2.3 Brazil	6
2.4 Sub-Saharan Africa	8
2.5 Conclusions	12

## **3. Pathogenesis in *Leishmania*/HIV coinfecting patients**

3.1 Pathogenesis in VL/HIV coinfecting patients	14
3.2 Pathogenesis in CL/HIV coinfecting patients	14

## **4. Diagnosis and microbiological aspects of the *Leishmania*/HIV coinfection**

4.1 Diagnosis in VL/HIV coinfecting patients	15
4.2 Microbiological aspects in <i>Leishmania</i> /HIV coinfecting patients	18
4.3 Conclusions on diagnosis	19

## **5. Treatment and secondary prophylaxis of visceral leishmaniasis in HIV-coinfecting patients**

5.1 Treatment of the coinfecting patient in southern Europe	21
5.2 Treatment of the coinfecting patient in India	22
5.3 Treatment of the coinfecting patient in Africa	22
5.4 Drugs for VL/HIV coinfection	23
5.5 Follow-up in VL/HIV coinfection	25
5.6 Conclusions on the treatment of VL in HIV-coinfecting patients	26
5.7 Recommendations for VL/HIV treatment in coinfecting patients	28

<b>Annex. List of participants</b>	<b>30</b>
------------------------------------	-----------



# 1. Introduction

The first case of leishmaniasis associated with human immunodeficiency virus (HIV) infection was reported in 1985, and the number of reported cases in southern Europe subsequently increased rapidly. Since that time, 35 countries have reported cases of coinfection.

In 1991, in order to achieve a better evaluation of the magnitude of the problem, WHO established a global network of 28 institutions. Initially, the sites involved in the network were predominantly European, reflecting the epidemiological situation at the time. Meetings held in Montpellier (1991), Rome (1994), Minorca (1998) and Catania (2001) documented the spread of *Leishmania*/HIV coinfection and covered topics that included routes of infection, pathogenesis, microbiological aspects, details of diagnosis and treatment, and secondary prophylaxis. Some documents produced by the network were:

- *Report on the Consultative Meeting on Leishmania/HIV coinfection, Rome, 6–7 September 1994*. Geneva, World Health Organization, 1995 (WHO/LEISH/95.35).
- *Leishmania/HIV coinfection. Weekly Epidemiological Record*, 1997, 72:49–56.
- Desjeux P. *Leishmania and HIV in gridlock*. Geneva, World Health Organization, 1998 (WHO/CTD/LEISH/98.23).
- Desjeux P et al. *Leishmania/HIV coinfection, south-western Europe 1990–98*. Geneva, World Health Organization, 2000 (WHO/LEISH/2000.42).
- Desjeux P, Alvar J, eds. *Leishmania/HIV co-infections. Annals of Tropical Medicine and Parasitology*, 2003, 97(Suppl.1).

After the introduction of antiretroviral therapy (ART) for HIV, the number of coinfecting cases reported in European *Leishmania*-endemic countries fell sharply. However, because of the increasing overlap of the two diseases, the problem of coinfection spread to the countries that are the world's major foci of leishmaniasis. The need to update epidemiological information regarding coinfection around the world and to prepare specific guidelines for case management in developing countries led WHO to organize the Fifth Consultative meeting on *Leishmania*/HIV Coinfection, which was held in Addis Ababa, Ethiopia, from 20 to 22 March 2007.

## 1.1 HIV/AIDS: statistics and features

Statistics for December 2006 show that some 39.5 million people are living with HIV/AIDS, of whom approximately 95% reside in developing countries. Of 4.3 million new HIV infections in 2006, 2.8 million (65%) occurred in sub-Saharan Africa, which continues to be the most severely affected part of the world. In several countries of this region, the impact of HIV has been to reduce adult life expectancy by 50%.

Although lack of access remains a major challenge, the number of people receiving ART in sub-Saharan Africa recently exceeded one million for the first time. Weakness of the health systems has been identified as a key obstacle to expanding treatment, care and preventive services. Ensuring compliance is another important issue: one of the lessons learned is that adherence to long-term therapy is improved by simplifying treatment and treating concurrent infections.

## 1.2 Leishmaniasis: statistics and features

As recognized in a resolution of the sixtieth World Health Assembly in 2007,<sup>1</sup> leishmaniasis is among the most neglected of the tropical diseases: more than 12 million people are currently infected worldwide, there are 2 million new cases every year (a number that is growing), and 350 million people are considered to be at risk. The disease affects the poorest populations in 88 countries (mostly developing countries). Two basic clinical forms are recognized – cutaneous leishmaniasis (CL), a disfiguring and stigmatizing disease, and visceral leishmaniasis (VL) or kala-azar, which is fatal without treatment.

The visceral form is present in 70 countries. The largest focus of VL is in the south-east Asian region, with an estimated 300 000 cases in 2006. East Africa has approximately 30 000 cases per year, and the third largest focus is in the Americas with 4000 cases reported in 2006. New foci are appearing at an alarming rate, and incidence in east Africa is on the increase. A lack of surveillance systems and the frequency of misdiagnosis (especially confusion with malaria) mean that true incidence is underestimated; failure to diagnose the disease leads to increased case-fatality rates. Post-kala-azar dermal leishmaniasis (PKDL) is a complication of VL, often occurring after apparently successful treatment of kala-azar. It requires a prolonged course of treatment: patients are highly infectious to sandflies and thus form an important component of the infection reservoir, especially in areas where transmission cycles are solely or predominantly anthroponotic.

Cutaneous leishmaniasis is present in at least 82 countries, with an annual estimated incidence of 1.5 million cases worldwide. Several clinical forms are recognized: localized CL, which often heals without treatment, diffuse CL, which is very difficult to treat, and mucosal leishmaniasis, which is the most severe form, producing disfiguring lesions and mutilation of the face.

## 1.3 *Leishmania*/HIV coinfection: statistics and features

The HIV/AIDS pandemic has modified the natural history of leishmaniasis disease. HIV infection increases the risk of developing VL by a factor of between 100 and 1000 in endemic areas, reduces the likelihood of therapeutic response, and greatly increases the probability of relapse. At the same time, VL promotes clinical progression of HIV disease and the development of AIDS-defining conditions. Because the two diseases target similar immune cells, together they exert a synergistic damaging effect on the cellular immune response. Atypical presentations of leishmaniasis are reported in HIV

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_29563](https://www.yunbaogao.cn/report/index/report?reportId=5_29563)

